论文部分内容阅读
目的:探讨MAC方案治疗急性髓细胞白血病的疗效。方法:对40例患者采用MAC方案治疗,对照组60例采用HA方案进行治疗。结果:观察组40例中完全缓解(CR)33例,CR率82.5 %,对照组60例中CR43例,CR率71.7 %,观察组CR率高于对照组,但无统计学差异(P =0.2)。观察组1疗程CR率显著高于对照组(P =0.025)。观察组中位生存时间29个月高于对照组的10个月,但无统计学差异(P =0.2)。结论:MAC方案治疗急性髓细胞白血病有较好的疗效,其毒副作用可以耐受,可用于急性髓细胞白血病的一线治疗。
Objective: To investigate the efficacy of MAC regimen in the treatment of acute myeloid leukemia. Methods: Forty patients were treated with MAC regimen and 60 control subjects with HA regimen. Results: The complete remission (CR) in 33 cases in observation group was 33 and the CR rate was 82.5%. The CR rate was 71.7% in 60 cases of control group. The CR rate of observation group was higher than that of control group (P = 0.2). The CR rate in observation group 1 was significantly higher than that in control group (P = 0.025). The median survival time of the observation group was 29 months higher than that of the control group, but there was no significant difference (P = 0.2). Conclusion: The MAC regimen has a good curative effect in the treatment of acute myeloid leukemia. Its toxic and side effects can be tolerated. It can be used in first-line treatment of acute myeloid leukemia.